Additionally, recombinant peptide nanoparticles (MtrapNPs) mimic ARF to sequester MDM2, stabilizing p53 and enhancing its tumor-suppressive effects while also delivering ATO as a salvage therapy for p53-mutant tumors [117]. The gene discussed is MDM2; the disease is neoplasm.